Sk grna bland "Frgor & svar" nedan, fr att se om din frga finns besvarad sedan tidigare
BPC-157, TB-500, GHK-Cu, and KPV working together for healing, inflammation control, and tissue regeneration
The core direction of future research should focus on directly verifying the causal relationship between local joint ferroptosis and gut microbiota dysbiosis through germ-free OA mouse models, fecal microbiota transplantation experiments, or conditional knockout models of key genes for chondrocyte-specific ferroptosis (such as GPX4 and ACSL4)
In addition, an IC supports the well-being of its members by creating an environment where collaboration leads to tangible change, reinforcing the idea that democratic processes can drive effective climate action
FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research
The catalase-SKL (serine-lysine-leucine) therapy reduced the pathophysiology of microglial activation while causing no memory loss by lowering the concentration of H 2 O 2 [96]
